UBRISA

View Item 
  •   Ubrisa Home
  • Faculty of Medicine
  • Internal Medicine
  • Research articles (Dept of Internal Medicine)
  • View Item
  •   Ubrisa Home
  • Faculty of Medicine
  • Internal Medicine
  • Research articles (Dept of Internal Medicine)
  • View Item
    • Login
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Alanine transaminase and hemoglobin appear to predict the occurrence of antituberculosis medication hepatotoxicity; findings and implications in Botswana

    Thumbnail
    View/Open
    Main article (847.8Kb)
    Date
    2020-12-01
    Author
    Kesenogile, Boikobo
    Godman, Brian
    Rwegerera, Godfrey Mutashambara
    Publisher
    Taylor & Francis. www.tandfonline.com
    Link
    https://www.tandfonline.com/doi/full/10.1080/14787210.2020.1822735
    Type
    Published Article
    Metadata
    Show full item record
    Abstract
    Objective: Tuberculosis (TB) remains a global health problem, with medications having adverse effects including drug-induced hepatotoxicity. We determined the prevalence of anti-tuberculosis drug-induced hepatotoxicity and associated risk factors. Methods: Retrospective cross-sectional study in Botswana including TB patients admitted from 1 June 2017 to 30 June 2018. Anti-TB drug-induced hepatotoxicity was categorized according to WHO criteria whereas causality assessment was made according to the updated Roussel Uclaf Causality Assessment Method (RUCAM) scale. The association between hepatotoxicity and included variables was undertaken by binary logistic regression. Results: Out of 112 patient files, 15 (13.4%) developed hepatotoxicity after an average of 20.4 days from the start of treatment. Grade 3 and 4 hepatotoxicity was found in 66.7% of the cases. According to the updated RUCAM tool, 86.7% of patients were categorized as having possible anti-TB-associated hepatotoxicity. Patients with elevated baseline alanine transaminase (ALT) were more likely to develop hepatotoxicity (OR = 3.484, 95% CI = 1.02–11.90). Patients with normal hemoglobin (Hb ≥ 12 g/dl) were also more likely to develop hepatotoxicity (OR = 4.413, 95% CI = 1.160–14.8). Conclusion: Overall, normal hemoglobin and elevated baseline ALT levels were significantly associated with anti-TB drug-induced hepatotoxicity. Additional research is needed to explore this association further.
    URI
    http://hdl.handle.net/10311/2083
    Collections
    • Research articles (Dept of Internal Medicine) [36]

    DSpace software copyright © 2002-2015  DuraSpace
    Contact Us | Send Feedback
    Theme by 
    @mire NV
     

     

    Browse

    All of UBRISA > Communities & Collections > By Issue Date > Authors > Titles > SubjectsThis Collection > By Issue Date > Authors > Titles > Subjects

    My Account

    > Login > Register

    Statistics

    > Most Popular Items > Statistics by Country > Most Popular Authors